Bull
$211.45
情景价格
$387.700
-2.210 (-0.57%)收盘时
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Bio-Rad Laboratories Inc is a good buy right now due to its current price of $387.7, which is near the analyst price target of $390, indicating potential upside. The company has shown a robust year-to-date change of +27.00% and a solid quarterly performance with a non-GAAP EPS of $2.62, exceeding expectations by $0.87. However, the main risk is the forward P/E ratio of 42.735, suggesting that the stock may be overvalued if growth does not continue as expected.
RBC Capital
$390
2026-08-07
RBC Capital
2026-08-07
目标价
$390
Wells Fargo
$310
2026-05-25
Wells Fargo
2026-05-25
目标价
$310
RBC Capital
$320
2026-05-14
RBC Capital
2026-05-14
目标价
$320
Wells Fargo
$290
2026-05-01
Wells Fargo
2026-05-01
目标价
$290
Citi
$300
2026-04-07
Citi
2026-04-07
目标价
$300
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

GraftAssureDx Advances Toward FDA Marketing Authorization

Bio-Rad Laboratories Q2 2026 Earnings Call Insights

Bio-Rad Q2 Earnings Exceed Expectations

Bio-Rad to Report Q2 2026 Financial Results on August 4

Investment Comparison: Bio-Rad vs. Charles River Laboratories
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Bio-Rad Laboratories Inc is a good buy right now due to its current price of $387.7, which is near the analyst price target of $390, indicating potential upside. The company has shown a robust year-to-date change of +27.00% and a solid quarterly performance with a non-GAAP EPS of $2.62, exceeding expectations by $0.87. However, the main risk is the forward P/E ratio of 42.735, suggesting that the stock may be overvalued if growth does not continue as expected.
4 analysts cover BIO: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 340.00.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。